“Breakthrough in Tailor-Made Medicines”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

Cancer vaccine group Antigenics has successfully completed a clinical trial that researchers hope marks a real breakthrough for personalized vaccines. While attending the annual meeting of the American Society of Clinical Oncology, Antigenics presented the results from the trial, which showed that personalized vaccines lowered cancer levels in patients when paired with the leukemia drug Gleevac. According to Antigenics, cancer levels were reduced in seven out of eight patients, and two of those went into complete remission. Support in the medical community for tailor-made medicines has grown in recent years as scientists have come to understand that there are many subsets within diseases.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.